This webpage was developed to provide the public with easy access to important drug safety information. The webpage contains the most recent Drug Safety Communications from FDA as well as links for Early Communications, Follow-Up Early Communications, Information for Healthcare Professional sheets, and Public Health Advisories issued prior to January 29th, 2010. You can also find drug specific information using the Index to Drug-Specific Information.
Starting July 18, 2011, you can find Spanish language versions of the Drug Safety Communications on our Drug Safety Communications in Spanish page.
El 18 de julio de 2011, se pueden encontrar versiones en español de las Comunicaciones de Seguridad de Medicamentos en nuestra Comunicaciones de la FDA sobre la seguridad de los medicamentos en español de la página.
Current Drug Safety Communications
FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor)
FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI)
FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide)
FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes
- FDA Drug Safety Communication: FDA evaluating the potential risks of using codeine cough-and-cold medicines in children